该产品被引用文献
1, Reiter, K; et al. Separation of virus-like particles and extracellular vesicles by flow-through and heparin affinity chromatography. Journal of Chromatography A, Pubmed: 30616980
2, Taylor, JP; et al. CRISPR/Cas9 knockout of USP18 enhances type I IFN responsiveness and restricts HIV-1 infection in macrophages. J. Leukoc. Biol., Pubmed: 29437254
3, Trifone, C; et al. Interaction Between Macrophage Migration Inhibitory Factor and CD74 in Human Immunodeficiency Virus Type I Infected Primary Monocyte-Derived Macrophages Triggers the Production of Proinflammatory Mediators and Enhances Infection of Unactivated CD4+ T Cells. Front Immunol, Pubmed: 29330478
4, 张晓. et al. 沙粒病毒进入抑制剂体外药效学评价模型的建立. 药学学报
5, Zhang, X; et al. Identification of a clinical compound losmapimod that blocks Lassa virus entry. Antiviral Res., Pubmed: 3953674
6, Yonekawa, M; et al. Suppression of R5-type of HIV-1 in CD4+ NKT cells by Vδ1+ T cells activated by flavonoid glycosides, hesperidin and linarin. Sci Rep, Pubmed: 31101837
7, Strobl, F; et al. Evaluation of screening platforms for virus-like particle production with the baculovirus expression vector system in insect cells. Sci Rep, Pubmed: 31974440
8, Tang, K; Zhang, X; Guo, Y. Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry. Acta Pharmaceutica Sinica B
9, Puente-Massaguer, E; Gòdia, F; Lecina, M. Development of a non-viral platform for rapid virus-like particle production in Sf9 cells. Journal of Biotechnology